Viron B, Michel C, Mignon F
Service de néphrologie, hôpital Tenon, Paris.
Rev Prat. 1991 Apr 21;41(12):1050-4.
The development, diversification and improvement of haemodialysis and transplantation techniques have radically altered the prognosis of end-stage chronic renal failure, a condition that is still inexorably lethal in many countries. In France, it is estimated that up to 20,000 patients are being kept alive by these treatments, including transplantation. The available follow-up data show that a survival of 30 years, and perhaps more, can now be expected, at the cost of cardiovascular and osteo-articular complications the incidence and severity of which should be reduced in the years to come. It is by a carefully planned recourse, based on each patient's clinical status and occupation, to the whole range of these complementary treatments that survival time and quality will be further improved.
血液透析和移植技术的发展、多样化及改进，已从根本上改变了终末期慢性肾衰竭的预后。在许多国家，这种疾病仍然无可避免地致命，但在法国，据估计有多达20000名患者通过包括移植在内的这些治疗得以存活。现有的随访数据表明，目前有望实现30年甚至更长时间的存活，但代价是心血管和骨关节并发症，在未来几年应降低这些并发症的发生率和严重程度。通过根据每位患者的临床状况和职业，精心规划采用所有这些辅助治疗方法，存活时间和质量将得到进一步改善。
